Shots:

• Evotec has received $6M as milestones under its iPSC-based neuroscience alliance with BMS. The milestones follow BMS’ decision to add another drug discovery project to the partnership’s portfolio
• In 2016- the companies collaborated to identify disease-modifying treatments for neurodegenerative diseases
• The partnership b/w both the companies has found several access points into neurodegenerative diseases and to-date delivered a broad portfolio targeting key disease mechanisms in neurodegeneration

 ­ Ref: Evotec | Image: Bristol Myers Squibb